High Skp2/low p57Kip2 expression is associated with poor prognosis in human breast Carcinoma: Supplementary issue: Breast cancer detection and screening

Breast Cancer: Basic and Clinical Research

Volumn 9, Issue , 2015, Pages 13-21

  Yang, Chengcheng ^a   Nan, Haocheng ^a   Ma, Jiequn ^a   Jiang, Lili ^a   Guo, Qianqian ^a   Han, Lili ^a   Zhang, Yamin ^a   Nan, Kejun ^a   Guo, Hui ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Breast cancer; Degradation; P57Kip2; Prognosis; Skp2

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1C; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MUTANT PROTEIN; PROGESTERONE RECEPTOR; S PHASE KINASE ASSOCIATED PROTEIN 2; TUMOR MARKER;

ADULT; AGE; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PHASE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HALF LIFE TIME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; OVERALL SURVIVAL; PREDICTION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 84938906570     PISSN: None     EISSN: 11782234     Source Type: Journal    
DOI: 10.4137/BCBCR.S30101     Document Type: Article

References (36)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29.
2. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252-271.
3. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 2011;137(10):1409-1418.
4. Hu T, Guo H, Wang W, et al. Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma. Oncol Rep. 2013;30(4):1707-1714.
5. Nan K-J, Guo H, Ruan Z-P, Jing Z, Liu S-X. Expression of p57 (kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma. World J Gastroenterol. 2005;11(8):1237-1240.
6. Guo H, Lv Y, Tian T, et al. Downregulation of p57 accelerates the growth and invasion of hepatocellular carcinoma. Carcinogenesis. 2011;32(12):1897-1904.
7. Li JQ, Wu F, Usuki H, et al. Loss of p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol. 2003;23(6):1537-1543.
8. Guo J, Cai J, Yu L, Tang H, Chen C, Wang Z. EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci. 2011;102(3):530-539.
9. Lu M, Zhao Y, Xu F, Wang Y, Xiang J, Chen D. The expression and prognosis of FOXO3a and Skp2 in human ovarian cancer. Med Oncol. 2012;29(5):3409-3415.
10. Rosenberg E, Demopoulos RI, Zeleniuch-Jacquotte A, et al. Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol. 2001;32(8):808-813.
11. Larson PS, Schlechter BL, King CL, et al. CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer. 2008;8(1):68.
12. Yang X, Karuturi RK, Sun F, et al. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One. 2009;4(4):e5011.
13. Xu XY, Wang WQ, Zhang L, et al. Clinical implications of p57KIP2 expression in breast cancer. Asian Pac J Cancer Prev. 2012;13(10):5033-5036.
14. Nijjar T, Wigington D, Garbe JC, Waha A, Stampfer MR, Yaswen P. p57KIP2 expression and loss of heterozygosity during immortal conversion of cultured human mammary epithelial cells. Cancer Res. 1999;59(20):5112-5118.
15. Moggs JG, Murphy TC, Lim FL, et al. Anti-proliferative effect of estrogen in breast cancer cells that re-express ERα is mediated by aberrant regulation of cell cycle genes. J Mol Endocrinol. 2005;34(2):535-551.
16. Rodriguez BA, Weng YI, Liu TM, et al. Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells. Carcinogenesis. 2011;32(6):812-821.
17. Zhang H, Kobayashi R, Galaktionov K, Beach D. pl9skp1 and p45skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell. 1995;82(6):915-925.
18. Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M. Significance of skp2 expression in primary breast cancer. Clin Cancer Res. 2006; 12(4):1215-1220.
19. Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002;110(5): 633-641.
20. Traub F, Mengel M, Luck HJ, Kreipe HH, von Wasielewski R. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat. 2006; 99(2):185-191.
21. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13(1):41-47.
22. Kamura T, Hara T, Kotoshiba S, et al. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci U S A. 2003;100(18): 10231-10236.
23. Sutterlüty H, Chatelain E, Marti A, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol. 1999;1(4):207-214.
24. Nakayama K, Nagahama H, Minamishima YA, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication. EMBO J. 2000;19(9):2069-2081.
25. Pateras IS, Apostolopoulou K, Koutsami M, et al. Downregulation of the KIP family members p27KIP1 and p57KIP2 by SKP2 and the role of methylation in p57KIP2 inactivation in nonsmall cell lung cancer. Int J Cancer. 2006;119(11):2546-2556.
26. Davidovich S, Ben-Izhak O, Shapira M, Futerman B, Hershko DD. Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer. Breast Cancer Res. 2008;10(4):R63.
27. Ravaioli A, Monti F, Regan MM, et al; International Breast Cancer Study Group. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Ann Oncol. 2008;19(4):660-668.
28. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCFSkp2-Cks1 ubiquitin ligase by the APC/CCdh1 ubiquitin ligase. Nature. 2004;428(6979):190-193.
29. Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I, Hershko DD. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer. 2005;103(7):1336-1346.
30. Susaki E, Nakayama K, Yamasaki L, Nakayama KI. Common and specific roles of the related CDK inhibitors p27 and p57 revealed by a knock-in mouse model. Proc Natl Acad Sci U S A. 2009;106(13):5192-5197.
31. Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1and p57Kip2CDK inhibitors. Cell Cycle. 2014;9(12):2342-2352.
32. Chan CH, Morrow JK, Li CF, et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013; 154(3):556-568.
33. Wu L, Grigoryan AV, Li Y, Hao B, Pagano M, Cardozo TJ. Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol. 2012;19(12): 1515-1524.
34. Guo H, Tian T, Nan K, Wang W. p57: a multifunctional protein in cancer (review). Int J Oncol. 2010;36(6):1321-1329.
35. Pateras IS, Apostolopoulou K, Niforou K, Kotsinas A, Gorgoulis VG. p57KIP2: "Kip"ing the cell under control. Mol Cancer Res. 2009;7(12):1902-1919.
36. Yan Y, Frisen J, Lee M-H, Massague J, Barbacid M. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 1997;11(8):973-983.